CELL INTELLIGENCE · 肿瘤细胞治疗研究

敲除 NR4A 改善线粒体适应性以延长人 CAR-T 细胞抗实体瘤的持久性

NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors.

NR4A 因子通过线粒体基因表达调控 CAR-T 细胞的持久性和干性，因此 NR4A 是生成针对实体瘤的优质 CAR-T 细胞的高度有前景的靶点。

基因编辑技术改善过继免疫治疗中的抗肿瘤 T 细胞功能

Gene editing technology to improve antitumor T-cell functions in adoptive immunotherapy.

靶向 FLT3 特异性 CAR-T 细胞治疗伴 KMT2A 重排的急性淋巴细胞白血病

Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement.

肝细胞癌过继性细胞治疗的现状及开发“现货型”疗法的挑战

Current Landscape of Adoptive Cell Therapy and Challenge to Develop "Off-The-Shelf" Therapy for Hepatocellular Carcinoma.

利用人诱导多能干细胞生成嵌合抗原受体巨噬细胞

Generation of chimeric antigen receptor-macrophages by using human induced pluripotent stem cells.

TCR-T 与 CAR-T 细胞疗法广泛应用的工程化策略

Engineering strategies for broad application of TCR-T- and CAR-T-cell therapies.

自然杀伤 T 细胞癌症免疫治疗的进展：同种异体和基因编辑细胞的应用

Progress in Natural Killer T Cell-Based Immunotherapy for Cancer: Use of Allogeneic and Gene-Edited Cells.